TR200001018T2 - Alzheimer hastalığının tedavi yöntemi. - Google Patents

Alzheimer hastalığının tedavi yöntemi.

Info

Publication number
TR200001018T2
TR200001018T2 TR2000/01018T TR200001018T TR200001018T2 TR 200001018 T2 TR200001018 T2 TR 200001018T2 TR 2000/01018 T TR2000/01018 T TR 2000/01018T TR 200001018 T TR200001018 T TR 200001018T TR 200001018 T2 TR200001018 T2 TR 200001018T2
Authority
TR
Turkey
Prior art keywords
carbon atoms
hydrogen
alzheimer
disease
treatment method
Prior art date
Application number
TR2000/01018T
Other languages
English (en)
Inventor
Robert Howlett David
Elizabeth Mitchell Davina
Original Assignee
Boehringer Mannheim Phar.Corp. Smithkline Beckman Corp.
Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Phar.Corp. Smithkline Beckman Corp., Ltd. filed Critical Boehringer Mannheim Phar.Corp. Smithkline Beckman Corp.
Publication of TR200001018T2 publication Critical patent/TR200001018T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Alzheimer hastaliginin tedavisinde ve amiloid hastaliklarin tedavisinde kullanilan, farmasötik olarak kabul edilebilir bir tuz olan bilesik ile tedavi yöntemi olup Formül (I):R7-R13 bagimsiz olarak -H veya -OH; ve A ise H, -OH veya formül (II)' nin bir parçasi olup R1 hidrojen, 6 karbon atomuna kadar allcanoil veya benzoil ve naftoil' den seçilmis aroil olup; R2 hidrojen, 6 karbonatomuna kadar alt alkil veya benzil, feniletil ve fenilpropil' den seçilmis arialkil; R3 hidrojen veya 6 karbon atomuna kadar alt alkil; R4 hidrojen veya 6 hidrojen atomuna kadar alt dahil, veya X' in oksijen oldugu halde, R4 ve R5 birlikte -CH2-O-' yu temsil edebilir; X bir deger bagi ise, -CH2, oksijen veya kükürt, Ar ise fenil, naftil, idanil ve tetrahidroaftil' den seçilmis; R5 ve R6 münferit olarak hidrojen, flor, klor, brom, hidroksil, 6 karbon atomuna kadar alt dahil, bir-CONH2- grubu, 6 karbon atomuna kadar alt alkisulfinil ve 6 karbon atomuna kadar alt alkilsulfonil; veya DEVAMI VAR.
TR2000/01018T 1997-10-15 1998-10-15 Alzheimer hastalığının tedavi yöntemi. TR200001018T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6236697P 1997-10-15 1997-10-15

Publications (1)

Publication Number Publication Date
TR200001018T2 true TR200001018T2 (tr) 2000-08-21

Family

ID=22042015

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01018T TR200001018T2 (tr) 1997-10-15 1998-10-15 Alzheimer hastalığının tedavi yöntemi.

Country Status (16)

Country Link
US (1) US6358990B1 (tr)
EP (1) EP1024697A4 (tr)
JP (1) JP2001519364A (tr)
KR (1) KR100573352B1 (tr)
CN (1) CN1281334A (tr)
AU (1) AU751526B2 (tr)
BR (1) BR9814075A (tr)
CA (1) CA2305262A1 (tr)
HU (1) HUP0100024A3 (tr)
IL (1) IL135584A (tr)
NO (1) NO20001869L (tr)
NZ (1) NZ504419A (tr)
PL (1) PL339910A1 (tr)
TR (1) TR200001018T2 (tr)
WO (1) WO1999018794A1 (tr)
ZA (1) ZA989365B (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142175A1 (de) * 2001-10-09 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung von ß-Adrenozeptor-Agonisten zur Behandlung von neurodegenerativen Erkrankungen
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP1499310A4 (en) * 2002-04-30 2005-12-07 Sb Pharmco Inc MONOCITRATE MONOHYDRATE OF CARVEDILOL
US20050261355A1 (en) * 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
MXPA04012923A (es) * 2002-06-27 2005-03-31 Sb Pharmco Inc Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
CN1991364A (zh) * 2005-12-26 2007-07-04 中国科学院上海生命科学研究院 预防和治疗阿尔兹海默症的g蛋白偶联受体拮抗剂
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2008021552A2 (en) * 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
LT2247558T (lt) 2008-02-14 2022-04-11 Eli Lilly And Company Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui
CN103172643B (zh) * 2011-12-26 2016-03-02 中国医学科学院药物研究所 黄皮咔唑生物碱及其制备方法和其药物组合物与用途
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
WO2014210544A2 (en) * 2013-06-27 2014-12-31 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
CA3192905A1 (en) * 2020-09-17 2022-06-23 Sui Rong Wayne CHEN Methods of treating and/or preventing alzheimer's disease with r-carvedilol

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
IE60991B1 (en) * 1986-12-17 1994-09-07 Glaxo Group Ltd Use of ketone derivatives in the treatment of cognitive disorders
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
JPH0558998A (ja) * 1991-09-06 1993-03-09 Taisho Pharmaceut Co Ltd カルバゾール誘導体
CN1166169A (zh) * 1994-07-27 1997-11-26 三共株式会社 用作毒蕈碱性受体别构效应物的杂环化合物
FR2724933A1 (fr) * 1994-09-22 1996-03-29 Pf Medicament Nouveaux ethers aromatiques derives d'indoles utiles comme medicaments
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
FR2731222A1 (fr) * 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
JPH11505526A (ja) * 1995-05-01 1999-05-21 ユニヴァーシティ・オヴ・ピッツバーグ アルツハイマー病の死前診断ならびにアミロイド沈着のイン・ビボのイメージ化及び予防のためのアゾ化合物

Also Published As

Publication number Publication date
PL339910A1 (en) 2001-01-15
HUP0100024A3 (en) 2002-12-28
NZ504419A (en) 2002-11-26
NO20001869L (no) 2000-06-14
US6358990B1 (en) 2002-03-19
IL135584A0 (en) 2001-05-20
AU751526B2 (en) 2002-08-22
CA2305262A1 (en) 1999-04-22
NO20001869D0 (no) 2000-04-11
EP1024697A1 (en) 2000-08-09
KR100573352B1 (ko) 2006-04-25
AU1089799A (en) 1999-05-03
BR9814075A (pt) 2000-09-26
CN1281334A (zh) 2001-01-24
ZA989365B (en) 1999-04-15
WO1999018794A1 (en) 1999-04-22
KR20010031108A (ko) 2001-04-16
EP1024697A4 (en) 2007-05-02
HUP0100024A2 (hu) 2001-07-30
IL135584A (en) 2005-12-18
JP2001519364A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
TR200001018T2 (tr) Alzheimer hastalığının tedavi yöntemi.
EP0911340A3 (de) Substituierte Isochinolin-3-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
BG46454A3 (en) Method for preparing of 2- (2'- nitrobenzoil)- 1, 3- cyclohexandions
RU2003107304A (ru) Промежуточные соединения для получения производных 3-гидрокси-4-арил-5-оксопиразолина с гибридным действием
ES2098357T3 (es) Derivado de indol.
ATE17249T1 (de) 9-(2-(3-indolyl)aethyl)-1-oxa-4,9diazaspiro(5.5)undecan-3-one.
NZ528997A (en) Sulfonamides
FI906296A (fi) Nya metylenbisfosfonsyrederivat.
DK58288A (da) Cyclopropancarboxylsyreestere, fremgangsmaade til deres fremstilling samt deres anvendelse til bekaempelse af parasitter
ES2078970T3 (es) Nuevos derivados del acido metilenbisfosfonico.
HUP0203622A2 (hu) Biciklusos vazopresszin agonisták és ezeket tartalmazó gyógyszerkészítmények
PE47596A1 (es) Derivado de quinoxalina util en terapia
DK0804186T3 (da) Indolditerpenalkaloidforbindelser
SE8002545L (sv) Arylsubstituerade furaner och sett for framstellning derav
AU539870B2 (en) 2-phenylamino-imidazolines-(2)
TR200102205T2 (tr) Anti-konvülsan türevlerinin bulimia nevruza tedavisinde kullanılmaları.
GR3024063T3 (en) 3H,6H-1,4,5a,8a-Tetraazaacenaphthylene-3,5-(4H)-diones
ATE112779T1 (de) Verfahren zur herstellung von 6-(d(-)-alpha-(4- äthyl-2,3-dioxo-1-piperazin-carboxamido)- phenylacetamido>penicillansäure.
MX9306388A (es) Procedimiento y compuestos intermedios para la obtencion de 2-fenil-5-(3-fenoxifenil)-1,1,1-trifluoropentanos
FI870067A (fi) Metionin-substituerade 1,4-dihydropyridiner, foerfarande foer deras framstaellning och deras anvaendning.
ATE17485T1 (de) 3,7a-diazacyclohepta(j,k)fluorenderivate, ihre herstellung und ihre therapeutische verwendung.
ATE38226T1 (de) Benzoylharnstoffe.
EP0173152A3 (en) Benzoyl ureas
DK231787A (da) 3-amino-dihydropyridiner, fremgangsmaade til deres fremstilling og deres anvendelse i laegemidler
PE60296A1 (es) Nueva sulfonamida